SensoDetect Technology in new doctoral thesis at Lund University.

No Comments

PhD student at the child and adolescent psychiatry at the University of Lund and chief physician Emma Claesdotter, defended on Friday her thesis “Auditory Brainstem Response (ABR) and Cambridge Neurophysiological Test Automated Battery (CANTAB) as Objective Support in Diagnosing Childhood ADHD and ASD”. Claesdotter has examined children and adolescents with ADHD and ASD with SensoDetect

View Full Post

Patent granted in Australia

No Comments

Patent- System and method for improved determination of a brain response state in Australia has now been granted and SensoDetect have achieved the registrings- and approvalpapers via the patent attorney AWA patent. The patent is valid until 2037. For further reading go to AktieTorget. 

Bolivia distributor to visit SensoDetect in Sweden

No Comments

SensoDetect is discussing a collaboration with one of Bolivia’s major distributors. The distributor has contacted SensoDetect regarding cooperation during last year and a first meeting and presentation took place at the beginning of the year in Bolivia. After dialogue during the spring and summer the distributor will now visit Sweden for further talks.   For

View Full Post

Patent Euroasia ready for national registration

No Comments

EuroAsia patents 2108550EA has been granted. The SensoDetects main portfolio is approved in the Euroasia (Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Russia, Tajikistan and Turkmenistan) area. IP portfolio strenghtens through this in especially one very important market, Russia.   In these countries, there is similar problems in Psychiatry as in the rest of the world.

View Full Post

Proof of the methodology

No Comments

The technology from SensoDetect has been proven through research. A recent blind study at Uppsala University Hospital published in 2017, using SensoDetect technology concluded “The ABR profiling tests discriminated schizophrenia and ADHD versus healthy controls with high sensitivity and specificity”. For further reading, go to AktieTorget.

Vivantes hospital in Berlin chooses SensoDetect Technology

No Comments

Vivantes hospital in Berlin will use Sensodetect Technology to measure impact of dialyses on patiens with kidney disease.   One of the main challenges for patients with kidney disease is the impact dialysis has on the brain (structural brain abnormalities and cognitive impairment). This can lead to the patient not attending treatments or mismanaging their

View Full Post
×

Make an appointment and we’ll contact you.

Translate »